253 related articles for article (PubMed ID: 27154416)
1. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
3. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
[TBL] [Abstract][Full Text] [Related]
4. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR
Hsu PY; Wu VS; Kanaya N; Petrossian K; Hsu HK; Nguyen D; Schmolze D; Kai M; Liu CY; Lu H; Chu P; Vito CA; Kruper L; Mortimer J; Chen S
Clin Cancer Res; 2018 Jan; 24(2):395-406. PubMed ID: 29079660
[No Abstract] [Full Text] [Related]
5. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L
Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
7. New generation breast cancer cell lines developed from patient-derived xenografts.
Finlay-Schultz J; Jacobsen BM; Riley D; Paul KV; Turner S; Ferreira-Gonzalez A; Harrell JC; Kabos P; Sartorius CA
Breast Cancer Res; 2020 Jun; 22(1):68. PubMed ID: 32576280
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
9. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
Lefley D; Howard F; Arshad F; Bradbury S; Brown H; Tulotta C; Eyre R; Alférez D; Wilkinson JM; Holen I; Clarke RB; Ottewell P
Breast Cancer Res; 2019 Nov; 21(1):130. PubMed ID: 31783893
[TBL] [Abstract][Full Text] [Related]
10. Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.
Landuzzi L; Palladini A; Ceccarelli C; Asioli S; Nicoletti G; Giusti V; Ruzzi F; Ianzano ML; Scalambra L; Laranga R; Balboni T; Arigoni M; Olivero M; Calogero RA; De Giovanni C; Dall'Ora M; Di Oto E; Santini D; Foschini MP; Cucchi MC; Zanotti S; Taffurelli M; Nanni P; Lollini PL
Sci Rep; 2021 Jan; 11(1):1563. PubMed ID: 33452364
[TBL] [Abstract][Full Text] [Related]
11. Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.
Yagishita S; Nishikawa T; Yoshida H; Shintani D; Sato S; Miwa M; Suzuki M; Yasuda M; Ogitani Y; Jikoh T; Yonemori K; Hasegawa K; Hamada A
Clin Cancer Res; 2023 Jun; 29(12):2239-2249. PubMed ID: 36976261
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
13. Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts.
Okano M; Oshi M; Butash A; Okano I; Saito K; Kawaguchi T; Nagahashi M; Kono K; Ohtake T; Takabe K
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):27-36. PubMed ID: 32109311
[TBL] [Abstract][Full Text] [Related]
14. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
[TBL] [Abstract][Full Text] [Related]
15. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
[TBL] [Abstract][Full Text] [Related]
16. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
18. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.
Richard E; Grellety T; Velasco V; MacGrogan G; Bonnefoi H; Iggo R
J Pathol; 2016 Nov; 240(3):256-261. PubMed ID: 27447842
[TBL] [Abstract][Full Text] [Related]
19. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
20. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
